Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8660578 | 0.95 | EDNRB (0.90) | EDNRBEDNRA | |
| SCHEMBL8804417 | 0.92 | EDNRB (0.86) | EDNRBEDNRA | |
| SCHEMBL8802029 | 0.92 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL892538 | 0.91 | EDNRB (1.00) | EDNRBEDNRA | |
| SCHEMBL8659179 | 0.91 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8801607 | 0.91 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8661143 | 0.91 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8801251 | 0.91 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL8662305 | 0.91 | EDNRB (0.84) | EDNRBEDNRA | |
| SCHEMBL7206507 | 0.91 | EDNRB (0.83) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0658548-B1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO (JP) | 1997-11-19 | — | — | EP | claimed |
| US-5589478-A | ENDOTHELIN ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-31 | — | — | US | claimed |
| EP-0658548-A1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-21 | — | — | EP | claimed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020012977-A1 | Enzymatic oxidations | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
| US-5728706-A | ENDOTHELIN ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0658548-B1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO (JP) | 1997-11-19 | — | — | EP | disclosed |
| US-5589478-A | ENDOTHELIN ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0658548-A1 | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO., LTD. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | EDNRB 8/4885EDNRA 11/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRB 7/4885EDNRA 11/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRB 148/4885EDNRA 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.